Background: Brazil is a country of continental scale, marked by profound social, geographic, and environmental diversity. Its population is one of the most genetically admixed in the world, shaped by complex contributions from Indigenous peoples, Europeans, Africans, and, to a lesser extent, Asian ancestries. Despite this heterogeneity, Brazilian populations remain underrepresented in global cancer genomics databases, largely dominated by North American, European, and East Asian cohorts. This lack of representation limits understanding of how genetic diversity, environmental exposures, and social determinants intersect to influence cancer development, prognosis, and treatment response in Brazil. This distinctive genetic landscape underscores the need for national initiatives capable of generating representative and integrated cancer data. The Atlas of Tumoral Profiles – Brazil (ATPBR) was conceived as a strategic response to this challenge. ATPBR is a nationwide effort designed to establish a FAIR-compliant (Findable, Accessible, Interoperable, Reusable) data infrastructure for storing, integrating, and analyzing clinical and multi-omics data from Brazilian cancer patients, supporting equitable precision oncology and global inclusion of Brazilian cancer diversity in research. Objectives: To develop and implement a national platform for secure integration and use of clinical and molecular cancer data from Brazilian patients, enabling representative research, strengthening cancer surveillance, and supporting evidence-informed precision oncology in Brazil. Methods: The platform enables secure submission, storage, and sharing of comprehensive metadata and high-quality sequencing datasets. The workflow begins with data ingestion, registering project, patient, and sample metadata alongside sequencing files. Data are organized in standardized directories under strict integrity, security, and governance protocols. Bioinformatic analyses are performed using validated NF-core pipelines to ensure reproducibility and analytical consistency. Non-sensitive analytical outputs are made publicly available through an interactive visualization portal. Platform development follows coordinated action plans to achieve independent project milestones. Results: Completed steps include definition of standardized metadata variables, design of barcoding systems enabling interoperability between the National Tumor Biobank and ATPBR datasets, and development of a functional prototype integrating all workflow stages. Bioinformatics pipelines have been extensively tested for reliability and reproducibility. Automated scripts are being optimized to streamline integration across storage, analysis, access, and visualization. Preliminary multi-omics results have been uploaded to the interactive portal, currently under customization. These developments establish foundational capacity for standardized, population-scale cancer data integration in Brazil. Conclusions: ATPBR represents a strategic advancement for Brazilian oncology research and cancer surveillance, providing secure, standardized, and reusable datasets that capture the genomic diversity of the Brazilian population. By enabling robust population-level analyses and data-driven discoveries, ATPBR supports evidence-based cancer control, promotes equitable access to precision medicine, and positions Brazil as a key contributor to global cancer research and international comparative initiatives. Funding: Programa Genomas Brasil, Ministério da Saúde, National Council for Scientific and Technological Development (CNPq), Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) and INCT Cancer Genomics and Precision Medicine for the SUS.